Mutations induced by monofunctional and bifunctional phosphoramide mustards in supF tRNA gene

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 381, Issue 1, 1997, Pages 49-57

  Mudipalli, Anuradha ^a   Maccubbin, Alexander E ^a   Nadadur, Srikanth S ^a   Struck, Robert F ^b   Gurtoo, Hira L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Ames test; Dechloroethyl phosphoramide mustard; Mutation specificity; Phosphoramide mustard; Relative mutagenicity; Shuttle vector

Indexed keywords

PHOSPHORAMIDE MUSTARD;

AMES TEST; ARTICLE; GENE MUTATION; MUTAGENICITY; MUTATION RATE; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; SHUTTLE VECTOR;

ALKYLATING AGENTS; BASE SEQUENCE; CELL LINE; GENES, SUPPRESSOR; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENICITY TESTS; MUTAGENS; MUTATION; PHOSPHORAMIDE MUSTARDS; PLASMIDS; RNA, TRANSFER; STRUCTURE-ACTIVITY RELATIONSHIP;

BRASSICACEAE;

EID: 0030784724     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(97)00147-4     Document Type: Article

References (48)

1. O.M. Friedman, A. Myles, M. Colvin, Cyclophosphamide and related phosphoramide mustards: current status and future perspectives, in: A. Rosowsky (Ed.), Advances in Cancer Chemotherapy, Marcel Dekker, New York, 1979, pp. 143-204.
2. M. Colvin, B.A. Chabner, Alkylating agents, in: B.A. Chabner, J.M. Collins (Eds.), Cancer Chemotherapy: Principles and Practice, T.B. Lippincott, Philadelphia, 1991, pp. 276-313.
3. Cohen J.L., Jao J.Y. Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat. J. Pharmacol. Exp. Ther. 174:1970;206-210.
4. Connors T.A., Cox P.J., Farmer P.B., Foster A.B., Jarman M. Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem. Pharmacol. 23:1974;115-124.
5. Sladek N.E. Biology and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo. Cancer Res. 33:1973;1150-1158.
6. Struck R.F., Kirk M.C., Witt M.H., Laster W.R. Jr. Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite. Biomed. Mass Spectrom. 2:1975;46-52.
7. Colvin M., Brundrett R.B., Kan M.N., Jardine I., Fenselau C. Alkylating properties of phosphoramide mustard. Cancer Res. 36:1976;1121-1126.
8. Mehta J.R., Przybylski M., Ludlum D.B. Alkylation of guanosine and deoxyguanosine by phosphoramide mustard. Cancer Res. 40:1980;4183-4186.
9. Vu V.T., Fenselau C.C., Colvin O.M. Identification of three alkylated nucleotide adducts from the reaction of guanosine-5′-monophosphate with phosphoramide mustard. J. Am. Chem. Soc. 103:1981;7362-7364.
10. Mehta J.R., Ludlum D.B. Trapping of DNA-reactive metabolites of therapeutic or carcinogenic agents by carbon-14-labeled synthetic polynucleotides. Cancer Res. 42:1982;2996-2999.
11. Chetsanga C.J., Polidori G., Mainwaring M. Analysis and excision of ring opened phosphoramide mustard-deoxyguanosine adducts in DNA. Cancer Res. 42:1982;2616-2621.
12. Kallama S., Hemminki K. Alkylation of guanosine by phosphoramide mustard, chloromethine hydrochloride and chlorambucil. Acta Pharmacol. Toxicol. 54:1984;214-220.
13. Hemminki K. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice. Cancer Res. 45:1985;4234-4237.
14. Crook T.R., Souhami R.L., McLean A.E.M. Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells. Cancer Res. 46:1986;5029-5034.
15. Benson A.J., Martin C.N., Garver R.C. N-(2-hydroxethyl)-N-[2-(7-guaninyl)ethyl]amine, the putative major adduct of cyclophosphamide in vitro and in vivo in the rat. Biochem. Pharmacol. 37:1988;2979-2985.
16. Hengstler J.G., Fuchs J., Oesch F. DNA strand breaks and DNA cross-links in peripheral mononuclear blood cells of ovarian cancer patients during chemotherapy with cyclophosphamide/carboplatin. Cancer Res. 52:1992;5622-5626.
17. Cushnir J.R., Naylor S., Lamb J.H., Farmer P.B., Brown W.A., Mirkes P.E. Identification of phosphoramide mustard/DNA adducts using tandem mass spectrometry. Rapid Commun. Mass Spectrom. 4:1990;410-414.
18. Maccubbin A.E., Caballes L., Riordan J.M., Huang D.H., Gurtoo H.L. A cyclophosphamide/DNA phosphoester adduct formed in vitro and in vivo. Cancer Res. 51:1991;886-892.
19. Benedict W.F., Baker M.S., Haroun L., Choi E., Ames B.N. Mutagenicity of cancer chemotherapeutic agents in the Salmonella/Microsome test. Cancer Res. 37:1977;2209-2213.
20. Fox M., Scott D. The genetic toxicology of nitrogen and sulphur mustard. Mutation Res. 75:1980;131-168.
21. Hales B.F. Comparison of mutagenicity and teratogenicity of cyclophosphamide and its active metabolites, 4-hydroxycyclophosphamide, phosphoramide mustard, and acrolein. Cancer Res. 42:1982;3016-3021.
22. Hemminki K., Kallama S., Kalck F. Correlations of alkylating activity and mutagenicity in bacteria of cytostatic drugs. Acta Pharmacol. Toxicol. 53:1983;421-428.
23. Arnsdorff-Roubicek D., Targa H.J. Mutagenic activity of metabolites contained in the plasma of Sprague-Dawley rats treated with cyclophosphamide. Mutation Res. 243:1990;309-312.
24. 1-3 cells by cancer chemotherapeutic agents. Cancer Res. 37:1977;2202-2208.
25. Benedict W.F., Banerjee A., Venkatesan N. Cyclophosphamide-induced oncogenic transformation, chromosomal breakage, and sister chromatid exchange following microsomal activation. Cancer Res. 38:1978;2209-2213.
26. Wilmer J.L., Erexson G.L., Kilgerman A.D. Attenuation of cytogenetic damage by 2-mercaptoethane-sulfonate in cultured human lymphocytes exposed to cyclophosphamide and its reactive metabolites. Cancer Res. 46:1986;203-210.
27. Povirk L.F., Shuker D.E. DNA damage and mutagenesis induced by nitrogen mustards. Mutation Res. 318:1994;205-226.
28. Wang P., Bennett R.A.O., Povirk L.F. Melphalan induced mutagenesis in an SV-40 based shuttle vector: predominance of A·T→T·A transversions. Cancer Res. 50:1990;7527-7531.
29. Wang P., Bauer G.B., Bennett R.A.O., Povirk L.F. Thermolabile adenine adducts and A·T base pair substitutions induced by nitrogen mustard analogues in an SV40-based shuttle plasmid. Biochemistry. 30:1991;11515-11521.
30. Routledge M.N., Wink D.A., Keefer L.K., Dipple A. Mutations induced by saturated aqueous nitric oxide in the pSP189 supF gene in human Ad293 and E. coli MBM 7070 cells. Carcinogenesis. 14:1993;1251-1254.
31. Juedes M.J., Wogan G.N. Peroxynitrite-induced mutation spectra of pSP189 following replication in bacteria and human cells. Mutation Res. 349:1996;51-61.
32. Courtemanche C., Anderson A. Shuttle vector mutagenesis by aflatoxin B1 in human cells: effects of sequence context on the supF mutational spectrum. Mutation Res. 306:1994;143-150.
33. Mudipalli A., Nadadur S.S., Maccubbin A.E., Gurtoo H.L. Mutations induced by dacarbazine activated with cytochrome P-450. Mutation Res. 327:1995;113-120.
34. Maron D.M., Ames B.N. Revised methods for the Salmonella mutagenicity test. Mutation Res. 113:1983;173-215.
35. J. Sambrook, E.F. Fritsch, T. Maniatis, Molecular Cloning, A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
36. Parris C.N., Seidman M.M. A signature element distinguishes siblings and independent mutations in a shuttle vector plasmid. Gene. 117:1992;1-5.
37. Poole B.L., Bos R.P., Niemeyer U., Theuws J.L.A., Schmahl D. In vitro/in vivo effects of Mesna on the genotoxicity and toxicity of cyclophosphamide - a study aimed at clarifying the mechanism of Mesna's anticarcinogenic activity. Toxicol. Lett. 41:1988;49-56.
38. 7 alkylation by nitrogen mustards. Nucleic Acids Res. 14:1986;2971-2987.
39. Kunz B.A., Mis J.R. Mutational specificities of 1,3-bis-(2-chloroethyl)-1-nitrosourea and nitrogen mustard in the SUP4-0 gene of Saccharomyces cerevisiae. Cancer Res. 49:1989;279-283.
40. Kallama S., Hemminki K. Stabilities of 7-alkylguanosines and deoxyguanosines formed by phosphoramide mustards and nitrogen mustard. Chem. Biol. Interact. 57:1986;85-96.
41. Barbarella G., Tugnol V., Zambanchi M. Imidazole ring opening at 7-methylguanosine at physiological pH. Nucleosides Nucleotides. 10:1991;1759-1769.
42. O'Connor T.R., Boiteux S., Laval J. Ring-opened 7-methylguanine residues in DNA are a block to in vitro DNA synthesis. Nucleic Acids Res. 16:1988;5879-5894.
43. Loeb L.A. Apurinic sites as mutagenic intermediates. Cell. 40:1985;483-484.
44. Loeb L.A., Preston B.D. Mutagenesis by apurinic/apyrimidinic sites. Annu. Rev. Genet. 20:1986;201-230.
45. Lawrence C.W., Borden A., Banerjee S.K., LeClerc J.E. Mutation frequency and spectrum resulting from a single abasic site in a single-stranded vector. Nucleic Acids Res. 18:1990;2153-2157.
46. 7 adducts as a mutagenic mechanism. Genetics. 129:1991;981-989.
47. O'Connor P.M., Kohn K.W. Comparative pharmacokinetics of DNA lesion formation and removal following treatment of L1210 cells with nitrogen mustards. Cancer Commun. 2:1990;387-394.
48. Ojwang J.O., Grueneberg D.A., Loechler E.L. Synthesis of a duplex oligonucleotide containing a nitrogen mustard interstrand DNA-DNA cross-link. Cancer Res. 49:1989;6529-6537.